Hanall Biopharma Co., Ltd.Hanall Biopharma Co., Ltd.Hanall Biopharma Co., Ltd.

Hanall Biopharma Co., Ltd.

No trades
Market capitalization
‪2.13 T‬KRW
‪−1.80 B‬KRW
‪138.94 B‬KRW
‪33.46 M‬
Beta (1Y)
0.80
Employees (FY)
318
Change (1Y)
+6 +1.92%
Revenue / Employee (1Y)
‪436.93 M‬KRW
Net income / Employee (1Y)
‪−5.68 M‬KRW

About Hanall Biopharma Co., Ltd.


Headquarters
Daejeon
Founded
1973
Identifiers
2
ISINKR7009420001
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.

Check out other big names from the same industry as 009420.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
069500
Samsung KODEX 200 ETF
Weight
0.08%
Market value
‪5.54 M‬
USD
VSS
Vanguard FTSE All-World ex-US Small-Cap ETF
Weight
0.03%
Market value
‪3.63 M‬
USD
244580
Samsung KODEX BIO ETF
Weight
1.69%
Market value
‪2.71 M‬
USD
463050
TIMEFOLIO TIMEFOLIO Kbio Active ETF Units
Weight
0.90%
Market value
‪2.43 M‬
USD
102110
Mirae Asset Tiger 200 ETF
Weight
0.08%
Market value
‪2.23 M‬
USD
278530
Samsung KODEX 200 Total Return ETF
Weight
0.08%
Market value
‪2.03 M‬
USD
SCHC
Schwab International Small-Cap Equity ETF
Weight
0.04%
Market value
‪1.91 M‬
USD
143860
Mirae Asset Tiger Health Care ETF
Weight
0.98%
Market value
‪1.58 M‬
USD
148020
KB RISE 200 Securities ETF(Equity) Units
Weight
0.08%
Market value
‪1.09 M‬
USD
227540
MIRAE ASSET TIGER 200 HEALTH CARE ETF
Weight
3.80%
Market value
‪969.21 K‬
USD
266420
SAMSUNG KODEX Healthcare ETF
Weight
0.98%
Market value
‪660.46 K‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of 009420 is 42,650 KRW — it has increased by 1.67% in the past 24 hours. Watch Hanall Biopharma Co., Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange Hanall Biopharma Co., Ltd. stocks are traded under the ticker 009420.
009420 stock has fallen by −13.14% compared to the previous week, the month change is a −5.95% fall, over the last year Hanall Biopharma Co., Ltd. has showed a 28.08% increase.
We've gathered analysts' opinions on Hanall Biopharma Co., Ltd. future price: according to them, 009420 price has a max estimate of 50,000.00 KRW and a min estimate of 40,000.00 KRW. Watch 009420 chart and read a more detailed Hanall Biopharma Co., Ltd. stock forecast: see what analysts think of Hanall Biopharma Co., Ltd. and suggest that you do with its stocks.
009420 reached its all-time high on Dec 1, 2025 with the price of 57,100 KRW, and its all-time low was 400 KRW and was reached on Aug 9, 2004. View more price dynamics on 009420 chart.
See other stocks reaching their highest and lowest prices.
009420 stock is 4.44% volatile and has beta coefficient of 0.80. Track Hanall Biopharma Co., Ltd. stock price on the chart and check out the list of the most volatile stocks — is Hanall Biopharma Co., Ltd. there?
Today Hanall Biopharma Co., Ltd. has the market capitalization of ‪2.13 T‬, it has decreased by −13.17% over the last week.
Yes, you can track Hanall Biopharma Co., Ltd. financials in yearly and quarterly reports right on TradingView.
Hanall Biopharma Co., Ltd. revenue for the last quarter amounts to ‪41.50 B‬ KRW, despite the estimated figure of ‪41.20 B‬ KRW. In the next quarter, revenue is expected to reach ‪40.40 B‬ KRW.
009420 net income for the last quarter is ‪298.96 M‬ KRW, while the quarter before that showed ‪598.77 M‬ KRW of net income which accounts for −50.07% change. Track more Hanall Biopharma Co., Ltd. financial stats to get the full picture.
No, 009420 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 20, 2025, the company has 318 employees. See our rating of the largest employees — is Hanall Biopharma Co., Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Hanall Biopharma Co., Ltd. EBITDA is ‪7.42 B‬ KRW, and current EBITDA margin is 2.41%. See more stats in Hanall Biopharma Co., Ltd. financial statements.
Like other stocks, 009420 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Hanall Biopharma Co., Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Hanall Biopharma Co., Ltd. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Hanall Biopharma Co., Ltd. stock shows the strong buy signal. See more of Hanall Biopharma Co., Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.